EU/3/10/838

About

Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in June 2011 on request of the sponsor.

On 23 February 2011, orphan designation (EU/3/10/838) was granted by the European Commission to Pharma Mar S.A. Sociedad Unipersonal, Spain, for plitidepsin for the treatment of post-essential thrombocythaemia myelofibrosis.

Key facts

Active substance
Plitidepsin
Disease / condition
Treatment of post-essential thrombocythaemia myelofibrosis
Date of first decision
23/02/2011
Outcome
Withdrawn
EU designation number
EU/3/10/838

Review of designation

Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in June 2011 on request of the sponsor, before a marketing authorisation had been granted.

Sponsor's contact details

Pharma Mar S.A. Sociedad Unipersonal
Avda. De los Reyes 1
Polígono Industrial La Mina
28770 Colmenar Viejo
Madrid
Spain
Telephone: +34 91 846 60 00
Telefax: +34 91 823 60 01
pharmamar@pharmamar.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating